Ascendis Pharma A (ASND) Other Operating Expenses (2018 - 2025)

Ascendis Pharma A (ASND) has 8 years of Other Operating Expenses data on file, last reported at $138.7 million in Q4 2025.

• For the quarter ending Q4 2025, Other Operating Expenses fell 0.66% year-over-year to $138.7 million; the trailing twelve-month figure through Mar 2026 stood at $138.7 million (down 0.66% YoY), and the FY2025 full-year result was -$997.0 million, down 46.88% from the prior year.
• Other Operating Expenses slipped to $138.7 million in Q4 2025, from $139.6 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $139.6 million in Q4 2024 to a low of -$265.9 million in Q4 2022.
• A 5-year average of -$90.6 million and a median of -$227.1 million in 2023 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses declined 11.69% in 2022 and surged 161.44% in 2024, its largest moves.
• Tracing ASND's Other Operating Expenses over 5 years: stood at -$238.1 million in 2021, then dropped by 11.69% to -$265.9 million in 2022, then gained by 14.58% to -$227.1 million in 2023, then surged by 161.44% to $139.6 million in 2024, then retreated by 0.66% to $138.7 million in 2025.
• Business Quant data shows ASND's Other Operating Expenses at $138.7 million in Q4 2025, $139.6 million in Q4 2024, and -$227.1 million in Q4 2023.